Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure

Abstract

Long-term treatment with alfacalcidol is safe and might be beneficial for the preservation of bone mass in the pre-dialysis stages of CRF, most likely through a reduction in bone turnover as estimated from the changes of the biochemical bone markers.